All | Positive bleed | Negative bleed | Total | Test discrimination |
---|---|---|---|---|
High risk | 109 | 1617 | 1726 | Sensitivity 0.76 Specificity 0.64 PPV 6.3% NPV 98% +LR 2.1(CI 1.7 to 2.8) −LR 0.3 (CI 0.2 to 0.7) |
Not high risk | 34 | 2932 | 2966 | |
Total | 143 | 4549 | 4692 | |
Heparin (without GPI) | ||||
High risk | 90 | 1107 | 1197 | Sensitivity 0.80 Specificity 0.59 PPV 7.5% NPV 98.7% +LR 1.9 (CI 1.8 to 2.2) −LR 0.3(CI 0.2 to 0.5) |
Not high risk | 22 | 1631 | 1653 | |
Total | 112 | 2738 | 2850 | |
Bivalirudin (without GPI) | ||||
High risk | 19 | 505 | 524 | Sensitivity 0.65 Specificity 0.61 PPV 3.6% NPV 98.7% +LR 1.6 (CI 1.3 to 2.2) −LR 0.5 (CI 0.3 to 0.9) |
Not high risk | 10 | 795 | 805 | |
Total | 29 | 1300 | 1329 |
GIP, glycoprotein IIb/IIIa inhibitor; LR−, negative Likelihood Ratio; LR+, positive Likelihood Ratio; NPV, negative predictive value; PPV, positive predictive value.